These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 25886315)

  • 1. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
    Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
    Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
    J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller.
    Tao H; Hayashi T; Sano F; Takahagi A; Tanaka T; Matsuda E; Okabe K
    J Surg Res; 2013 Nov; 185(1):250-4. PubMed ID: 23830361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.
    Robinson CG; DeWees TA; El Naqa IM; Creach KM; Olsen JR; Crabtree TD; Meyers BF; Puri V; Bell JM; Parikh PJ; Bradley JD
    J Thorac Oncol; 2013 Feb; 8(2):192-201. PubMed ID: 23287852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.
    Stephans KL; Djemil T; Reddy CA; Gajdos SM; Kolar M; Mason D; Murthy S; Rice TW; Mazzone P; Machuzak M; Mekhail T; Videtic GM
    J Thorac Oncol; 2009 Aug; 4(8):976-82. PubMed ID: 19633473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraoperative pleural lavage cytology is an independent prognostic indicator for staging non-small cell lung cancer.
    Lim E; Ali A; Theodorou P; Nicholson AG; Ladas G; Goldstraw P
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1113-8. PubMed ID: 15052210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival.
    Roach MC; Rehman S; DeWees TA; Abraham CD; Bradley JD; Robinson CG
    Pract Radiat Oncol; 2016; 6(1):12-8. PubMed ID: 26598909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?
    Guckenberger M; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Grills IS
    J Thorac Oncol; 2012 Mar; 7(3):542-51. PubMed ID: 22258475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.